Evidence map›Paper›PMID 37509500›Full record

ArticleBiomedicines2023

Real-World Endoscopic and Histologic Outcomes in Ulcerative Colitis Patients: A Retrospective Cohort Study.

Monica State, Paul Balanescu, Theodor Voiosu, Andreea Bengus, Andrei Voiosu, Andrei Coman, Petronel Mustatea, Lucian Negreanu, Radu Bogdan Mateescu, Cristiana Popp

Abstract read
In one paragraph

Article in Biomedicines, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.

0numbers the graph read from it
0cells of the map it votes in
2citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

2 citing papers in PubMed.

  1. Article
  2. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

10 authors.

Monica StateGastroenterology Department, Colentina Clinical Hospital, 020125 Bucharest, Romania.ORCID 0000-0003-4961-3476
Paul BalanescuInternal Medicine Department, Carol Davila University of Medicine and Pharmacy, 050474 Bucharest, Romania.
Theodor VoiosuGastroenterology Department, Colentina Clinical Hospital, 020125 Bucharest, Romania.
Andreea BengusGastroenterology Department, Colentina Clinical Hospital, 020125 Bucharest, Romania.
Andrei VoiosuGastroenterology Department, Colentina Clinical Hospital, 020125 Bucharest, Romania.
Andrei ComanPathology Department, Colentina Clinical Hospital, 020125 Bucharest, Romania.
Petronel MustateaSurgery Department, Ion Cantacuzino Clinical Hospital, 011437 Bucharest, Romania.
Lucian NegreanuInternal Medicine Department, Carol Davila University of Medicine and Pharmacy, 050474 Bucharest, Romania.ORCID 0000-0003-3042-0754
Radu Bogdan MateescuGastroenterology Department, Colentina Clinical Hospital, 020125 Bucharest, Romania.ORCID 0000-0002-2607-8653
Cristiana PoppPathology Department, Colentina Clinical Hospital, 020125 Bucharest, Romania.

Funding

Romanian Ministery of Research and Innovation PN-III-P1-1.1-TE-2021-0801/2022
6 · The paper itself

Abstract

backgroundHistologic activity has emerged as an aspirational therapeutic goal in ulcerative colitis management. It is not yet a formal treatment target in ulcerative colitis. However, it could be used as an adjunct to mucosal healing to represent a deeper level of healing. We investigated mucosal and histologic remission rates and potential predictors of these outcomes in a cohort of UC patients.

methodsWe conducted a retrospective analysis of data collected from UC patients enrolled in an ongoing prospective cohort study. Mucosal healing was defined as Mayo endoscopic score = 0.

resultsA total of 131 patients with ulcerative colitis were enrolled in our study and were prospectively followed for a median length of 2 years (range 0-5 years), totaling 266 study visits. Mucosal healing was recorded for 27 patients at 70 (26%) different study visits. For patients with mucosal healing, histologic remission was achieved in 18/27 (66%) patients. On univariate analysis, sustained clinical remission, SIBDQ scores ≥ 5.5, CRP ≤ 5 mg/dL and absence of corticotherapy were associated with mucosal healing and SIBDQ scores ≥ 5.5 and CRP ≤ 5 mg/dL with histologic healing, respectively. After logistic regression analysis, none of the investigated factors were associated with mucosal and histologic healing. The number of CD8+ intraepithelial lymphocytes (IELs) was significantly greater than the number of CD4+ IELs in periods of disease activity, as well as during mucosal healing (

conclusionsMucosal healing and histologic remission rates are low in real-life settings. The results of univariate analysis indicate that a good quality of life (SIBDQ score) and normal inflammatory markers (CRP) are associated with mucosal and histologic healing. However, frequently used patient- and disease-related factors, including mucosal healing, are not reliable predictors for histologic remission. Greater CD8+ lymphocyte involvement and higher CD8+/CD4+ distribution can have a meaningful impact on understanding the pathogenesis and natural history of ulcerative colitis, as well as future treatment options for lymphocyte-targeting medications.

Indexed as

histologic healinginflammatory bowel diseasemucosal healingulcerative colitis

Identifiers

PMID37509500
PMCPMC10376510

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.